Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cep-32496. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 8/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cep-32496 SCHEMBL29697285 | 1.00 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL29351427 | 1.00 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL29726019 | 0.99 | BRAF (0.98) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL18155156 | 0.99 | BRAF (0.98) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL16156073 | 0.96 | BRAF (0.93) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL17053430 | 0.96 | BRAF (0.92) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1011649 | 0.95 | BRAF (0.91) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL17679303 | 0.94 | BRAF (0.90) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1013252 | 0.94 | BRAF (0.90) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1011900 | 0.94 | BRAF (0.90) | BRAFRAF1RIPK2JAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799503-B2 | Methods for the treatment of cancer | IGNYTA, INC. (US) | 2020-10-13 | — | — | US | claimed |
| US-20200069688-A1 | METHODS FOR THE TREATMENT OF CANCER | IGNYTA, INC. (US) | 2020-03-05 | — | — | US | claimed |
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | claimed |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | claimed |
| US-9987281-B2 | Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor | IGNYTA, INC. (US) | 2018-06-05 | — | — | US | claimed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | claimed |
| US-20170290833-A1 | SOLID STATE FORMS OF A QUINAZOLINE DERIVATIVE AND ITS USE AS A BRAF INHIBITOR | IGNYTA, INC. (US) | 2017-10-12 | — | — | US | claimed |
| US-9718810-B2 | Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor | IGNYTA, INC. (US) | 2017-08-01 | — | — | US | claimed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | claimed |
| EP-2947072-B1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | AMBIT BIOSCIENCES CORP (US) | 2016-11-09 | — | — | EP | claimed |
| US-20150376171-A1 | SOLID STATE FORMS OF A QUINAZOLINE DERIVATIVE AND ITS USE AS A BRAF INHIBITOR | IGNYTA, INC. | 2015-12-31 | — | — | US | claimed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | claimed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | claimed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | claimed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | claimed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | claimed |
| JP-2011529021-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | claimed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | BRAF 3/4885EGFR 793/4885RET 1/4885 |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | BRAF 3/4885EGFR 793/4885RET 1/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885EGFR 779/4885RET 46/4885 |
| US-20150376171-A1 | SOLID STATE FORMS OF A QUINAZOLINE DERIVATIVE AND ITS USE AS A BRAF INHIBITOR | BRAF, NRAS, RAF1 | BRAF 1/4885EGFR 130/4885RET 34/4885 |
| US-10799503-B2 | Methods for the treatment of cancer | RET, TP53, VHL | BRAF 26/4885EGFR 232/4885RET 1/4885 |
| US-20200069688-A1 | METHODS FOR THE TREATMENT OF CANCER | RET, TP53, VHL | BRAF 26/4885EGFR 232/4885RET 1/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885EGFR 504/4885RET 75/4885 |
| US-20170290833-A1 | SOLID STATE FORMS OF A QUINAZOLINE DERIVATIVE AND ITS USE AS A BRAF INHIBITOR | BRAF, NRAS, RAF1 | BRAF 1/4885EGFR 130/4885RET 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.